ACE inhibitors reduce the risk for progression of overt type 1 diabetic nephropathy to end-stage renal disease, and in patients with type 1 diabetes with microalbuminuria to overt nephropathy.
GLP-1 receptor antagonists have been shown to reduce albuminuria only, and their ability to slow progression to end-stage renal disease is not clear.
Learn more about slowing the progression of diabetic nephropathy.
Medscape © 2022 WebMD, LLC
Any views expressed above are the author's own and do not necessarily reflect the views of WebMD or Medscape.
Cite this: A. Brent Alper. Fast Five Quiz: Risk for Diabetic Nephropathy Progression - Medscape - Mar 22, 2022.
Comments